Potaba Shortage Update: What Patients Need to Know in 2026

If you've been prescribed Potaba (potassium aminobenzoate) and you're having trouble filling it, you may be wondering whether there's an official shortage — or whether you're just having bad luck at your local pharmacy. The honest answer is a bit of both. Here is what patients need to know about Potaba availability in 2026.

Potaba's Official Shortage Status in 2026

As of 2026, Potaba (potassium aminobenzoate) is not listed on the FDA's official Drug Shortage Database. This means the drug is being produced and distributed through normal channels — there is no manufacturer crisis, raw material issue, or regulatory hold driving a national shortage.

However — and this is important — the absence of a formal FDA shortage does not mean the medication is easy to obtain. Potaba is what pharmacy professionals call a "slow mover" or low-volume medication. Most pharmacies simply don't stock it because it's not prescribed frequently enough to justify shelf space.

Why Finding Potaba Feels Like a Shortage Even When It Isn't

From a patient perspective, there's not much practical difference between a formal drug shortage and a niche medication that isn't stocked locally. Either way, you can't fill your prescription without extra effort. The causes behind Potaba's scarcity at retail pharmacies include:

Small patient population: Peyronie's disease and scleroderma affect a relatively small number of patients. Low prescription volume means pharmacies have little incentive to keep Potaba on their shelves.

Shifting clinical guidelines: The AUA does not recommend Potaba as first-line therapy for Peyronie's disease. As urologists increasingly turn to Xiaflex injections, Potaba prescriptions have declined.

Challenging dosing regimen: At 12 grams per day in divided doses, patients need a large monthly supply. Storing and dispensing this volume is a burden for pharmacies already managing thousands of other products.

Limited manufacturer competition: Fewer companies manufacture potassium aminobenzoate compared to high-volume generics, meaning fewer distribution points and potentially longer lead times for special orders.

Historical Context: Has Potaba Been in Shortage Before?

Potaba has not historically been a drug on the FDA shortage radar. Unlike medications that suddenly face a supply crisis — such as the GLP-1 agonist shortage that dominated headlines from 2023–2025 — Potaba's availability challenges stem from chronic low demand rather than a sudden supply disruption. This has been the case for years and continues into 2026.

What Patients Should Do Right Now

If you can't find Potaba in stock, here are the most effective steps:

Use medfinder. medfinder.com calls local pharmacies on your behalf and texts you which ones have your medication in stock — saving you hours on the phone.

Try independent pharmacies. Independent and specialty pharmacies are more likely to carry or special-order niche medications than chain retailers.

Ask for a special order. Most pharmacies can order Potaba within 2–5 business days through their drug wholesaler.

Contact your prescriber. Let them know you're having trouble filling the prescription. They may have a recommended pharmacy or may discuss alternatives.

Consider compounding. Compounding pharmacies can prepare custom formulations of potassium aminobenzoate, which may be more accessible than the commercial product in some regions.

Don't Skip Doses While You Search

Potaba is typically used as a long-term treatment — often months of continuous therapy. If you run out while searching for a pharmacy, contact your prescriber immediately. Do not abruptly discontinue any prescription medication without medical guidance. Your doctor may be able to provide an emergency bridge prescription for an alternative or help locate a source quickly.

See also: Alternatives to Potaba If You Can't Fill Your Prescription for a detailed look at the treatment options your doctor may recommend.